Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

PROFIT ALERT

This announcement is made by Grand Pharmaceutical Group Limited (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of the directors (the "**Board**") of the Company would like to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the information currently available to the Company and the preliminary review by the management of the Company over the unaudited management accounts of the Group for the six months ended 30 June 2024, it is expected that the consolidated net profit attributable to owners of the Company increased by not less than 50% as compared with the same period of last year (profit attributable to owners of the Company for the six months ended 30 June 2023 amounted to HK$1,029,354,000). The major reasons (among other factors) for the increase were: 1) due to the fair value change in the Group's investment in Telix Pharmaceuticals Limited amounted to approximately HK$476,630,000, which increased by approximately HK$247,480,000 compared with same period in 2023; and 2) Other losses were resulted from an one-off expenses amounted to HK$323,390,000 for the six months ended 30 June 2023, there is no such expenses in 2024 and the Group recorded net other revenue.

The information contained in this announcement is only based on the preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2024 and the information currently available to the Board, and such information has not been reviewed by the Company's auditors or audit committee. The unaudited consolidated financial results of the Group for the six months ended 30 June 2024 have not been finalized and may be subject to adjustment. The announcement on the unaudited results of the Group for the six months ended 30 June 2022 is expected to be published on 19 August 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 14 August 2022

As at the date of this *announcement, the Board comprises three executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao and Mr. Yang Guang, and four independent non- executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.*

** For identification purpose only*